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efficacy issues. Though the prevalence of wild-type MeV 
infection has decreased by >90 % in Europe, measles is 
still not eliminated and has even re-emerged with recur-
rent outbreaks in developed countries, in which effective 
vaccination programmes had been installed for decades. 
Here, we discuss the crucial factors for a worldwide elim-
ination of MeV: (1) efficacy of current vaccines, (2) the 
extremely high contagiosity of MeV demanding a >95 % 
vaccination rate based on two doses to avoid primary 
vaccine failure as well as the installation of catch-up vac-
cination programmes to fill immunity gaps and to achieve 
herd immunity, (3) the implications of sporadic cases of 
secondary vaccine failure, (4) organisation, acceptance 
and drawbacks of modern vaccination campaigns, (5) 
waning public attention to measles, but increasing con-
cerns from vaccine-associated adverse reactions in socie-
ties with high socio-economic standards and (6) clinical, 
epidemiological and virological surveillance by the use 
of modern laboratory diagnostics and reporting systems. 
By consequent implementation of carefully designed epi-
demiologic and prophylactic measures, it should be pos-
sible to eradicate MeV globally out of mankind, as the 
closely related morbillivirus of rinderpest could be suc-
cessfully eliminated out of the cattle on a global scale.
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Basics
Measles is a highly contagious infectious disease caused 
by a RNA virus of the paramyxoviridae family in which 
it belongs to the genus morbillivirus. Other species of 
this genus are the canine distemper virus of dogs and the 
Abstract Measles virus (MeV) is an aerosol-borne and 
one of the most contagious pathogenic viruses known. 
Almost every MeV infection becomes clinically mani-
fest and can lead to serious and even fatal complications, 
especially under conditions of malnutrition in develop-
ing countries, where still 115,000 to 160,000 patients die 
from measles every year. There is no specific antiviral 
treatment. In addition, MeV infections cause long-lasting 
memory B and T cell impairment, predisposing people 
susceptible to opportunistic infections for years. A rare, 
but fatal long-term consequence of measles is subacute 
sclerosing panencephalitis. Fifteen years ago (2001), 
WHO has launched a programme to eliminate measles 
by a worldwide vaccination strategy. This is promis-
ing, because MeV is a human-specific morbillivirus (i.e. 
without relevant animal reservoir), safe and potent vac-
cine viruses are sufficiently produced since decades for 
common application, and millions of vaccine doses have 
been used globally without any indications of safety and 
On behalf of the Committee of Immunisation, Society of 
Virology (Germany, Austria, Switzerland).
 * Heidemarie Holzmann 
 Heidemarie.Holzmann@meduniwien.ac.at
 H. W. Doerr 
 H.W.Doerr@em.uni-frankfurt.de
1 Department of Virology, Medical University of Vienna, 
Vienna, Austria
2 Institute of Virology, University Medical Center,  
Albert-Ludwigs-University Freiburg, Freiburg, Germany
3 Department of Molecular and Medical Virology,  
Ruhr-University Bochum, Bochum, Germany
4 Institute for Medical Virology, Goethe-University Hospital 
Frankfurt, Frankfurt/M., Germany
202 Med Microbiol Immunol (2016) 205:201–208
1 3
rinderpest virus of cattle. These morbilliviruses are strictly 
host-specific, i.e. there is no virus transmission from ani-
mals to humans or vice versa in terms of epidemiologic 
relevance [1]. The measles virus (MeV) is a spheric par-
ticle with a diameter of approximately 200 nm. A layer 
of matrix proteins (M) beneath a cell membrane-derived 
lipid envelope covers a core complex consisting of non-
segmented, negative-sensed RNA genome packaged in 
nucleoprotein (N), large polymerase protein (L) and poly-
merase-associated protein (P). The glycoproteins H and F 
form spikes on the envelope. H mediates virus attachment 
to the receptors of the target cell (in vitro haemagglutina-
tion), and F mediates the fusion of the virus envelope with 
the cell membrane, thus releasing the core complex into the 
cell. Through fusion of neighboured cells (to multinuclear 
giant cells), the virus infection can be directly transmit-
ted. N is abundantly produced in infected cells. N and the 
other MeV proteins are presented to specific cytotoxic T 
lymphocytes via the MHC I system, while antibodies to H 
and F neutralise infectivity of virions. By sequencing 450 
nucleotides of the N gene (in the C terminal part), 24 geno-
types compiled in eight clades (A–H) have been identified. 
However, cross-neutralisations with strain-specific antisera 
revealed only one serotype [2].
MeV is air-borne transmitted by nasopharyngeal droplets. 
The virus is highly lymphotropic, infecting dendritic cells, 
alveolar macrophages and subsets of B and T cells in the 
lymphoid tissue of the lower respiratory tract before it infil-
trates the epithelium of the upper respiratory tract. MeV also 
spreads to the conjunctiva, skin and other organs, where it 
replicates primarily in endothelial cells, epithelial cells and 
macrophages [1, 2]. About eight (to 12) days post-infection, 
non-specific prodromi with cough, coryza and conjunctivitis 
develop and last for 2–4 days. At the end of this prodromal 
phase, the pathognomonic Koplik spots appear at the buc-
cal mucosa. About 12 days post-infection, an erythematous 
maculo-papular rash erupts and spreads usually from head 
over trunk to the extremities. Pyrexia is common and lasts 
approximately 1 week. Nearly everybody who is infected 
falls ill. A special feature of measles is a long-lasting gen-
eralised immunosuppression due to the loss of immune 
memory B and T cells resulting in an increased susceptibil-
ity to other infections even several years after recovery [3, 
4]. As a consequence, in many patients complications are 
observed, especially under the settings of malnutrition in 
developing countries. The majority of them are caused by 
bacterial superinfections, e.g. otitis media (7–9 %), pneu-
monia (1–6 % in industrialised countries, however, the most 
common cause of death in developing countries) or diar-
rhoea (8 %) [2, 5]. Post-infectious encephalitis occurs in 
approximately 0.1 % of the patients with resulting in fatal 
outcome in approximatively 20 % of those or leading to per-
manent sequelae in the majority of survivors [2]. In patients 
suffering from a pre-existing immunodeficiency, an “atypi-
cal” (i.e. MeV-induced) giant cell pneumonia can occur as a 
life-threatening event. In those patients, lethal acute progres-
sive encephalitis is also frequently observed. The reason for 
this severe course of the disease is that MeV-infected cells 
must be eliminated by T cell immunity, which is not fully 
working in such infants yet or may be impaired by other dis-
eases. If the T cell system is deficient, the patient is likely to 
fall ill with life-threatening “white” measles. The exanthe-
matic skin inflammations are lacking, but the virus dissemi-
nation in the body is enhanced [2]. Moreover, a sub-acute 
sclerosing panencephalitis (SSPE) may develop 1–10 years 
after apparent recovery from measles, especially after infec-
tion in the first year of age (because of a still immature T 
cell system). SSPE is associated with MeV strains escaping 
specific (humoral) immune responses persisting in neurons 
and glia cells of the brain. Mutations of M, F and H pro-
teins have been considered relevant [6, 7]. The prognosis 
of SSPE is lethal. The frequency has been re-evaluated in 
recent years and is much higher than assumed before with a 
reported rate of approximately 1:5000 [1]. In Germany, the 
risk of children contracting measles infection below 5 years 
of age has been calculated to be as high as 1:1700–1:3300, 
which is in the same order of magnitude as the risk of a 
fatal acute measles infection [8]. However, the big major-
ity of measles patients recover 1–2 weeks after the onset of 
exanthema, but remain in the following years susceptible to 
secondary infections due to the long-lasting memory B and 
T cell impairment.
Vaccination
Because of its high infectivity and spreading, a single per-
son with measles infects an average of 12 to 18 people in a 
fully susceptible population. This is a reproductive rate (R0) 
that is much higher in comparison with Ebola with 1.5–2.5 
or Influenza with 1.4–4 [5, 9]. Measles presented as a typi-
cal childhood disease before the start of infant vaccination 
programmes. The high morbidity had made measles a big 
burden to the public health. Moreover, because of relatively 
high rates of complications (20–30 %) and fatal outcomes 
with estimated 7–8 million children that died annually due to 
MeV infection in the pre-vaccination era, measles was com-
monly feared, although the majority of children recovered ad 
integrum. Thus, there was a big need for vaccination [1].
Vaccines were being developed soon after MeV had been 
isolated and propagated in human or monkey cell cultures, 
and available since 1963 [2, 5]. The first vaccine was an 
inactivated MeV strain. It did not provide a good and long-
lived protection, since some of the relevant parts of the F 
spike on the virus envelope were slightly denatured in the 
inactivation process. This is why the neutralising antibodies 
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raised by this dead vaccine did not reliably block wild-type 
MeV superinfection, and only provided a partial immunity 
(against the H spike). On the contrary, vaccine-induced 
antibodies sometimes enhanced the subsequent wild-type 
virus infection leading to a long-lasting pneumonia and 
death of the vaccinee (atypical measles infection) [5]. Con-
sequently, this vaccine was replaced by attenuated live 
MeV of genotype A, mainly derivatives of the 1954 iso-
lated Edmonston strain: “Further attenuated measles vac-
cines,” “Schwarz,” “Moraten,” etc. They had been devel-
oped by serial passages at different temperatures in human 
kidney, human amnion and embryonic chicken cell cultures 
[2, 5]. These vaccines, most often combined with mumps 
and rubella vaccines (MMR), were widely applied since 
decades and with hundreds of millions of doses adminis-
tered have been proven to be well tolerated, very safe and 
confer long-lasting protection [9, 10]. Adverse reactions are 
generally mild (e.g. fever occurs in 5–15 %, rash in 3–5 % 
of vaccinees) [5]. Less common adverse reactions with a 
frequency of 1 in 1000–1 in 10,000 vaccinated individuals 
are lymphadenopathy, swelling of parotid gland, diarrhoea, 
vomiting or febrile convulsions. Rare adverse events (<1 
in 10,000 vaccinated individuals) are urticaria, transient 
thrombocytopenia and deafness, meningitis/encephalitis 
in up to 1 per 100,000 or anaphylactic reactions in 1.5 per 
1,000,000 vaccinated individuals. In the vast majority of 
countries, vaccination has been introduced in routine child-
hood immunization programmes with the administration of 
two doses. The first dose (MCV1) should be administered, 
as soon as protecting maternal antibodies have vanished, 
usually at the age of 9–12 months [11]. The second vacci-
nation (MCV2) can be administered after a minimum inter-
val of 4 weeks and is often recommended to be given at 
the age of 15–18 months or, in countries with low measles 
transmission and high MCV1 coverage, even later [11]. 
During an epidemic with an increased risk of exposure, 
start of MMR vaccination can be recommended for infants 
as young as 6–9 months of age [5, 12]. However, because 
immunogenicity and effectiveness are lower than for doses 
administered at a later age, this early vaccination should be 
counted as “zero dose” (recorded as MCV0) and the child 
should subsequently receive both routine doses at the rec-
ommended ages according to the national schedule [12]. 
Several studies have shown that about 95 % of vaccines 
produce sufficient antibodies to be protected against mea-
sles after the first vaccination. The protection rate increases 
up to 99 % after the second vaccination [7, 13–18].
Global eradication of measles
From the beginning, common infant vaccination has dra-
matically reduced measles in all countries of the world, 
where programmes have been implemented consequently. 
For example, in the pre-vaccination era in the US measles 
outbreaks occurred every year with a median incidence 
rate of 317.1 cases per 100,000 population. After vaccine 
licensure (1963) and the start of vaccination programmes 
in 1970s, the incidence rates dropped >95 %. It has been 
calculated that since the introduction of the vaccine about 
35 million measles cases has been prevented [19]. Because 
of the impact of measles on global health, the lack of an 
animal reservoir and the availability of live-attenuated mea-
sles vaccines providing long-term immunity after admin-
istration of two doses [5, 20], the WHO (in collaboration 
with UNICEF and the Measles Initiative) launched a global 
immunization campaign against measles aiming for a 90 % 
reduction in measles-related mortality by 2010 [21]. In the 
American WHO region, measles was eliminated by 2002 
by reaching a high coverage of two doses of measles vac-
cine due to the full implementation of a vaccination strat-
egy including routine and supplementary immunization 
activities. This was proof of principle that measles elimi-
nation is feasible and practical. Because of the success of 
measles-associated mortality reduction and elimination 
efforts, five of the six WHO regions including the European 
adopted regional measles elimination targets initially by 
2010 and revised to 2015 [22]. This deadline could not be 
hold for several reasons [23] and was expanded until 2020 
[24]. To reach this aim and to stop endemic MeV transmis-
sion, a seamless vaccine uptake of at least 95 % with two 
doses of MMR vaccine is considered to be necessary in all 
countries. Even in countries which reached the elimination 
goal, local gaps in vaccine coverage can result in outbreaks 
due to imported MeVs [25].
Up to date, the worldwide campaign was very promis-
ing [25, 26], leading to a 78 % decline in estimated annual 
deaths globally from 562,400 in the year 2000 to 114,900 
in 2014. While the first dose of measles vaccine cover-
age increased globally from 72 to 85 % between 2000 and 
2010, it has remained unchanged the past four years [25]. In 
Europe, the number of measles cases dropped by 98 % from 
341,289 in 1993 to 7073 in 2007. However, since 2010, 
MeV activity rebounded with approximately 37,000 cases 
in 2014. In 2015, the sought elimination year in Europe, 
large outbreaks occurred again, and also Germany and Aus-
tria with more than 2500 and 300 cases, respectively, were 
affected. As a consequence of the increased MeV activity in 
certain countries, especially in China, the Philippines and 
Viet Nam, nations that have eliminated measles are con-
fronted the last years with an increased number of importa-
tions, which led, for example, in the USA to more than 600 
measles cases in the year 2014 and recently to the first mea-
sles death since 12 years. Thus, more efforts are urgently 
needed, which is discussed below, especially from the per-
spective of the European German-speaking countries.
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Challenges
In recent years, measles has had a comeback in popula-
tions in which effective vaccination programmes had been 
installed for decades, like in USA, Australia, England, Ger-
many and other European countries [9, 10] This has raised 
some key questions:
(1) Is the vaccine still efficient?
Does primary and secondary vaccine failure matter?
The live measles vaccine strain, which is commonly 
applied, has been isolated from a patient and propagated in 
embryonic chicken cell cultures as long as random mutations 
have attenuated its pathogenicity. Modern molecular biologic 
analysis has typed most vaccine viruses as members of the 
extinct genotype A, derived from the MeV strain Edmonston 
[27]. In contrast to the highly contagious wild-type virus, the 
vaccine virus is not infectious to immune-competent individ-
uals, and person-to-person transmission of vaccine virus has 
never been documented [5, 11]. To our current knowledge, 
every MeV strain starts the infection process by interaction of 
envelope glycoprotein H to virus-specific cell receptors, i.e. 
CD150, which is a signalling lymphocytic activation mole-
cule (SLAM), and CD46, which is an inhibitory complement 
receptor [1]. Obviously, vaccine MeV has got a crucial muta-
tion in the H gene which reduces its interaction with CD46. 
More important for the attenuation is the enhanced interferon 
induction of the vaccine virus in comparison with the wild 
type [28]. In addition, further mutations in MeV genome may 
contribute to attenuation. In particular, the L gene might be 
the target of in vitro artificial virus attenuation. Despite the 
fact that other MeV genotypes can replace indigenous geno-
types [29], there is no evidence for immune selection of such 
viruses in homogenously immunised populations. Forming 
conserved epitopes across genotypes MeV is antigenetically 
stable (no relevant escape mutants) [30–32]. Antisera from 
individuals infected decades ago retain the ability to neutral-
ise current wild-type (WT) strains of MeV and vice versa, 
although with different efficiency. In the recent measles out-
breaks, MeV strains of non-A genotypes, in particular type 
D, have been isolated [33–35]. Nevertheless, they can still be 
neutralised by anti-H antisera without significant restriction, 
indicating that the vaccines are still fully effective [30, 31]. 
The vast majority of measles patients in current outbreaks had 
not or not been sufficiently vaccinated, especially in terms of 
the second dose [10, 35, 36].
(2) Are the current vaccination programmes appropriate?
The timing of delivery strategies for the first and second 
vaccination dose varies across countries and regions. In 
countries with ongoing transmission, WHO recommends 
the administration of the first dose at the age of nine months 
to ensure optimal protection during the susceptible period in 
infancy. Re-vaccination is recommended in the second year 
of life (15–18 months) [11] to booster and prolong a strong 
immunity as well as to immunise individuals in which the 
first vaccination has failed (primary vaccine failure, see 
above). The minimum interval between the first and second 
dose is one month. Catch-up vaccination is recommended 
for all children, adolescents and adults, who have not 
received the first or second dose of MMR vaccine or have 
lost their vaccination records in most countries. However, 
in many European countries those catch-up vaccination 
programmes were not conducted or accepted efficiently. As 
a result, measles outbreaks are still occurring despite sig-
nificantly increasing vaccination rates with a majority of 
adolescents and young adults (up to 40 years of age) being 
affected, who were mainly not vaccinated against measles or 
had received only one dose. In addition, a high percentage 
of this age group is also not naturally immune against mea-
sles [37]. This lack of immunity leads to another complex 
problem: pregnant women of childbearing age, who were 
not protected against measles themselves, cannot provide 
vertical protection for their infants [37]. Furthermore, in the 
current epidemiological situation they are at risk to acquire 
measles in pregnancy, which is associated with a higher 
incidence of hospitalisation, measles-related complications 
(e.g. pneumonitis) including maternal death and adverse 
pregnancy outcomes like pregnancy loss, preterm birth and 
low birth weight, but not congenital defects [38–40]. Infec-
tions shortly before or after delivery can lead to intrauterine, 
perinatal or postnatal MeV infections of the newborn, who 
then have a high risk to develop SSPE due to their immature 
immune system [5, 8, 41, 42]. Because of all these aspects 
mentioned above, it has to be discussed, if additional efforts 
and other vaccination schedules are necessary to close the 
vaccination gaps [37].
Other setbacks why successful vaccination programmes 
were interrupted leading again to large vaccination gaps are 
catastrophes including life-threatening disease outbreaks 
like the Ebola epidemic in West Africa and wars (e.g. in 
Syria). Currently millions of refugees live in crowded 
camps or are travelling thousands of kilometres through 
different countries (part of them with ongoing large mea-
sles outbreaks, e.g., in Bosnia-Herzegovina, Serbia) to 
reach Central and Northern Europe. Because of the mass 
accumulations of migrants and the rapid migration move-
ments, there is a high risk of transmission and wide spread 
of infectious diseases, especially measles [43]. There is 
no possibility to vaccinate these masses of refugees dur-
ing their migration on the transit routes; however, in the 
accommodating countries like Germany and Austria, the 
MMR vaccination of refugees has the highest priority, 
although the organisation of those mass vaccinations is still 
205Med Microbiol Immunol (2016) 205:201–208 
1 3
a big challenge. In parallel, a rapid increase in the MMR 
vaccination rates of the native population is necessary to 
reduce the risk of large outbreaks.
How many people must be vaccinated to establish stable 
herd immunity for the population preventing virus trans-
mission and mediating protection for individuals who are 
not immune? This depends on the basic reproduction rate 
(R0), which indicates how many people on average are 
infected by an initial spreader in a fully susceptible pop-
ulation. For measles, the index has been calculated to be 
12–18, which is one of the highest for any human pathogen 
[24]. This demands that >94 % of a population has to be 
immune to stop virus spread (and to ensure herd immunity) 
[5, 9]. This high rate has been reached for smallpox, when 
the vaccination had been regulated by law in the most coun-
tries. Without such regulation, wild poliovirus type 2 (PV-
2) has been eradicated. The eradication of PV-3 is nearly 
reached [44]. However, PV-2 vaccine-derived strains and 
wild poliovirus type 1 strains are still circulating in some 
countries (Israel, West Africa, Afghanistan and Pakistan) 
[45–47]. The basic reproduction rate (R0) of poliovirus was 
calculated 4–13 [9]. Consequently, an immunity rate of 
about 85 % was necessary to effectively interrupt virus cir-
culation. This was reached by vaccination against poliovi-
rus type 2, while the rates for poliovirus 1 and 3 have been 
found to be sometimes lower [48]. However, a worldwide 
system of surveillance discovers and closes the gaps in all 
countries in which vaccination is strictly applied. To exceed 
a vaccination rate of 90 %, without regulation by law, is a 
big challenge for the public health system and seems like 
Sisyphean labour. Measles outbreaks happened when this 
line was underrun. For these reasons, additional efforts are 
absolutely necessary to increase vaccine acceptance.
Potentially alarming are, however, reports on sporadic 
cases of overt measles disease amongst adults, who received 
two doses of measles vaccine decades ago [5, 38, 49–52]. 
Some of the cases led to further transmission events and 
occurred typically in countries which have implemented 
their vaccination programmes early and successfully and 
thus achieved the WHO elimination goals, i.e. complete 
elimination of MeV transmission. These cases could indi-
cate that vaccine-induced IgG levels are waning [20, 53, 54] 
and the immunological memory to MeV is more limited in 
the absence of wild-type MeV exposure events than thought 
before. If cases of breakthrough measles due to secondary 
vaccine failure are seen more often, this should be an incen-
tive to enhance the speed of the elimination process!
(3) How to speed up the elimination process and arouse 
public opinion? Should vaccination be regulated by law?
After smallpox, no other vaccination has been so far reg-
ulated by law globally, since no other ubiquitously spread 
infectious disease was considered so life-threatening, espe-
cially when an anti-infective therapy is missing. The vac-
cination against smallpox produced many and severe side 
effects. The more smallpox waned, the more the vaccina-
tion was criticised and refused. Although the anti-MeV 
vaccination produces much less side effects, it becomes 
more and more neglected or even rejected when—as a con-
sequence of successful vaccination programmes—the dan-
gerous measles complications decline and disappear out 
of the public attention, while the fear of adverse effects is 
increasing [55]. Other factors that have an impact on vac-
cine uptake in countries with high socio-economical stand-
ards are complacency, lack of education about the serious-
ness of the disease and a degree of mistrust in the medical 
establishment and the pharmaceutical industry [1, 9]. This 
results in an increasing number of parents, who are scepti-
cal towards vaccination [9, 56, 57]. In opposite to oral vac-
cines, injections are being perceived as unpleasant for chil-
dren and parents. Therefore, combining several vaccines 
in one injection has proven to be a convenient approach. 
Such a combined vaccine has been introduced for mea-
sles, rubella and mumps and has been extended to vari-
cella (MMR, respectively, MMRV vaccine). It has revealed 
that the immunogenic infectivity of the single attenuated 
viruses is not impaired [58]. The combined vaccine should 
be applied not only for the primary immunisation, but also 
for secondary boosters to close immunity gaps deriving 
from the first vaccination. It has been proven very effec-
tive in elimination of poliomyelitis caused by three immu-
nologically different poliovirus types [59]. Complications 
of poliovirus infections are no more frequent than those 
from measles, but patients suffering from side effects such 
as paralysis are living amongst us as a visible and constant 
reminder of this issue. In opposite to poliomyelitis, mea-
sles are frequently considered as an unpleasant, but healing 
up disease of children, even by some medical doctors who 
believe that passed measles strengthens the power of resist-
ance. However, measles impair the immune system for a 
longer period of time in which other infectious diseases 
may happen. So, the public attention on measles must be 
enhanced and kept high aside of current measles outbreaks 
[9, 10].
(4) Is the measles surveillance system adequate?
Smallpox has been eradicated not only by vaccination, 
but also by an effective global reporting and surveillance 
system. Also for measles (and rubella) elimination a rapid, 
exact and sensitive surveillance system is of major impor-
tance. For the national health authorities, it is important 
that clinically suspected cases were reported rapidly and 
implemented control measures can be executed immedi-
ately. However, the virological surveillance and laboratory 
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performance play an essential role. In countries near elimi-
nation, all suspected cases should be routine laboratory 
confirmed and PCR samples of anti-MeV-IgM-positive 
samples sent to a national reference laboratory for further 
investigation. In some cases, interpretation of laboratory 
results is challenging (e.g. in persons with a recent his-
tory of vaccination, false-positive results because of cross-
reactivity with other infections, indeterminate test results 
or positive results for both measles and another virus like 
Parvovirus B19, Epstein Barr virus or human herpesvirus 
type 6). For the elucidation of transmission chains, the dif-
ferentiation of endemic circulation or the importation of 
MeV strains, differentiation of imported/imported-related 
measles cases and the interruption of transmission highly 
sensitive virological and molecular biological test methods 
(i.e. viral sequencing, genotyping and phylogenetic analy-
ses) are essential tools for the assessment of epidemiologi-
cal situation [60, 61].
Measles patients are on average most infectious four 
days before and after the onset of exanthema. Measles are a 
severe respiratory disease producing epidemiological issues 
similar to influenza. Global tourism and worldwide migra-
tion due to war and poor economic conditions pose addi-
tional challenges to the WHO project of measles eradica-
tion [9, 62]. Currently, Europe is affected by massive flows 
of refugees enhancing, in combination with an increas-
ing sceptical attitude of the Central European population 
towards vaccines, the risk of new outbreaks. Apart from 
that, in industrial countries, where measles had become 
rare, doctors are not so familiar with the clinical symp-
toms. In underdeveloped countries, malnutrition makes 
measles more severe and prolongs the period of infectiv-
ity. It has to be discussed whether immigrants and tropi-
cal tourists should be checked on measles immunity by 
antibody tests. Simple methods focus on oral fluid swabs 
saving blood sampling. However, with the current large 
migration streams in Europe, this would be not feasible, but 
the immediate administration of the MMR vaccine when 
the refugees reach their target country has a high priority. 
Reporting obligation has to be established and expanded in 
the public health system of every country. Modern molecu-
lar diagnostic tools are available for rapid tracing infectious 
chains [33, 63].
Conclusions
Measles can be best prevented by vaccination. Live-atten-
uated MeV strains, preferentially strain Enders/Schwarz, 
are used. Although they had been developed more than 
50 years ago, the currently used vaccines are very effec-
tive for establishing immune protection which lasts for 
several decades when the infants were vaccinated twice 
in their second year of life. MeV breakthrough infections 
have been recorded as exception of this rule. A large major-
ity of measles outbreaks in Europe which happened in the 
last five years have been caused by immunity gaps resulting 
from deficient participation in the vaccination programmes. 
More than 95 % of a population must be successfully vac-
cinated to stop MeV circulation and to prevent outbreaks 
after MeV re-import from countries in which measles are 
still endemic. These countries suffer from socio-economic 
problems, political riots, etc. and need special support from 
WHO and charity organisations. Paradoxically, also in 
developed countries the necessary rate of vaccine-immu-
nised people is underrun in some regions. This is reasoned 
by insufficient information on life-threatening complica-
tions due to measles. As a consequence of successful vac-
cination programmes, the public attention to this problem 
decreases even in medical doctors, who are today less 
familiar with this disease. Measles vaccine combined with 
rubella, mumps and possibly varicella will probably meet 
a bigger acceptance in the population. More sentinel pro-
grammes of laboratory immunity checks should be estab-
lished to discover gaps in herd immunity as early as pos-
sible [36]. If we succeed in increasing the acceptance of the 
measles vaccination and the awareness of the risks of MeV 
infections in our population, we really could—with the 
assistance of the effective combined vaccines—approach 
the major goal of regional measles elimination/worldwide 
eradication. Vaccination and surveillance programmes had 
successfully led to the eradication of poxviruses and had 
proven very useful in fighting the spread of poliomyelitis. 
Morbillivirus vaccines are effective, as the eradication of 
rinderpest virus (2010) has shown [64].
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